Evolution In Clinical Outcome Assessments Reflected In US FDA’s Revised Gastroparesis Guidance

 
• By Bridget Silverman

Agency recommends an anchor-based approach to statistical analyses of drug effects on core signs and symptoms.

Pulling-together
Guidance revision urges sponsors to use “an anchor-based approach, typically using Phase II trial data, to estimate clinically meaningful change” when defining endpoints.

More from Approval Standards

More from Pathways & Standards